Free tool
Drug Trial Radar: Gastroenterology and liver
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
310
Completed, industry sponsors, Gastroenterology and liver, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed310
310 trials
Showing 1 to 25, recently updated first.
- Phase 2b Study of GSK4532990 in Adults With NASHPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05583344 · 284 participants · Start Jan 2, 2023 · Primary completion Jan 31, 2026
Drug: GSK4532990; Placebo · For: Nonalcoholic Fatty Liver Disease; Non-alcoholic Fatty Liver Disease
Sites: Homewood, Alabama; Chandler, Arizona; Mesa, Arizona · 171 sites in all
- A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic GastroparesisPivotal-lookingCompleted
CinDome Pharma, Inc.Industry
NCT05832151 · 382 participants · Start Mar 27, 2023 · Primary completion Nov 14, 2025
Drug: CIN-102 Dose 15mg or 10mg; Placebo · For: Diabetic Gastroparesis
Sites: Dothan, Alabama; Foley, Alabama; Huntsville, Alabama · 100 sites in all
- A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05809934 · 220 participants · Start Mar 15, 2023 · Primary completion Jul 14, 2025
Drug: AZD2693 · For: Nonalcoholic Steatohepatitis
Sites: Chandler, Arizona; Peoria, Arizona; Surprise, Arizona · 163 sites in all
GlaxoSmithKlineGSK (GSK)
NCT06104319 · 61 participants · Start Jan 22, 2024 · Primary completion Sep 23, 2025
Drug: GSK4532990 · For: Non-alcoholic Fatty Liver Disease
Sites: Chula Vista, California; Montclair, California; San Diego, California · 14 sites in all
Processa PharmaceuticalsIndustry
NCT05270460 · 25 participants · Start Mar 9, 2022 · Primary completion Sep 29, 2022
Drug: PCS12852; Placebo · For: Gastroparesis
Sites: Lomita, California; San Diego, California; Miami, Florida · 9 sites in all
- A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive DysfunctionPivotal-lookingCompleted
Umecrine Cognition ABIndustry
NCT07304843 · 207 participants · Start Apr 14, 2023 · Primary completion Sep 9, 2026
Drug: golexanolone; golexanolone and 3 more · For: Primary Biliary Cholangitis (PBC)
Sites: Düsseldorf, Germany; Leipzig, Germany; Athens, Greece · 38 sites in all
- Different Doses of Naronapride vs. Placebo in GastroparesisPivotal-lookingCompleted
Dr. Falk Pharma GmbHIndustry
NCT05621811 · 328 participants · Start Jan 3, 2023 · Primary completion Aug 12, 2025
Drug: Naronapride; Placebo · For: Gastroparesis
Sites: Chula Vista, California; Lomita, California; Clearwater, Florida · 24 sites in all
Kowa Research Institute, Inc.Industry
NCT06247735 · 46 participants · Start Feb 7, 2024 · Primary completion Jun 26, 2025
Drug: K-808 (Dose A); K-808 (Dose B) and 1 more · For: Primary Biliary Cholangitis
Sites: Tucson, Arizona; Coronado, California; Los Angeles, California · 38 sites in all
- Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)Pivotal-lookingCompleted
Hanmi Pharmaceutical Company LimitedIndustry
NCT04505436 · 215 participants · Start Jul 31, 2020 · Primary completion Jun 26, 2026
Drug: HM15211; Placebo of HM15211 · For: NASH - Nonalcoholic Steatohepatitis
Sites: Huntsville, Alabama; Chandler, Arizona; Chula Vista, California · 60 sites in all
- A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)Pivotal-lookingCompleted
Corcept TherapeuticsIndustry
NCT06108219 · 175 participants · Start Oct 25, 2023 · Primary completion Feb 13, 2026
Drug: Miricorilant (Cohort A); Placebo (Cohort A) and 2 more · For: Nonalcoholic Steatohepatitis (NASH); Metabolic Dysfunction-associated Steatohepatitis (MASH)
Sites: Chandler, Arizona; Tucson, Arizona; Huntington Park, California · 77 sites in all
- Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in ChildrenPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT03339128 · 272 participants · Start Nov 15, 2017 · Primary completion Aug 17, 2026
Drug: Eluxadoline; Placebo · For: Irritable Bowel Syndrome
Sites: Hot Springs, Arkansas; Little Rock, Arkansas; Corona, California · 46 sites in all
- Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With FibrosisPivotal-lookingCompleted
Zydus Therapeutics Inc.Industry
NCT05011305 · 189 participants · Start Aug 18, 2021 · Primary completion Sep 12, 2025
Drug: Saroglitazar Magnesium 2 mg; Saroglitazar Magnesium 4 mg and 1 more · For: Nonalcoholic Steatohepatitis; Fibrosis
Sites: Birmingham, Alabama; Homewood, Alabama; Phoenix, Arizona · 129 sites in all
- Saroglitazar Magnesium for Treatment of Primary Biliary CholangitisPivotal-lookingCompleted
Zydus Therapeutics Inc.Industry
NCT05133336 · 196 participants · Start Apr 1, 2022 · Primary completion Apr 30, 2025
Drug: Saroglitazar Magnesium 1 mg; Saroglitazar Magnesium 2 mg and 1 more · For: Primary Biliary Cholangitis
Sites: Birmingham, Alabama; Tucson, Arizona; Los Angeles, California · 57 sites in all
Inventiva PharmaIndustry
NCT05232071 · 39 participants · Start Jun 29, 2022 · Primary completion May 8, 2024
Drug: Lanifibranor; Placebo and 1 more · For: NASH - Nonalcoholic Steatohepatitis; Diabetes Mellitus, Type 2
Sites: Homewood, Alabama; Chandler, Arizona; Conway, Arkansas · 42 sites in all
HighTide Therapeutics (Hong Kong) LimitedIndustry
NCT04604652 · 24 participants · Start May 27, 2021 · Primary completion May 31, 2022
Drug: HTD1801 (BUDCA) · For: Primary Biliary Cholangitis; Primary Biliary Cirrhosis; Cholangitis and 3 more
Sites: Miami, Florida; Atlanta, Georgia; Boston, Massachusetts · 12 sites in all
- A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)Pivotal-lookingCompleted
HighTide Therapeutics (Hong Kong) LimitedIndustry
NCT03656744 · 101 participants · Start Nov 26, 2018 · Primary completion Feb 7, 2020
Drug: HTD1801; Placebo · For: Fatty Liver, Nonalcoholic; NAFLD; Nonalcoholic Fatty Liver Disease and 3 more
Sites: Chandler, Arizona; Tucson, Arizona; Panorama City, California · 17 sites in all
ArdelyxIndustry
NCT06553547 · 72 participants · Start Jul 24, 2024 · Primary completion Jul 7, 2026
Drug: Tenapanor; Placebo · For: Irritable Bowel Syndrome With Constipation (IBS-C)
Sites: Little Rock, Arkansas; Hartford, Connecticut; Miami, Florida · 20 sites in all
- HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-DiabetesPivotal-lookingCompleted
HighTide Therapeutics (Hong Kong) LimitedIndustry
NCT05623189 · 218 participants · Start Dec 27, 2022 · Primary completion Mar 31, 2025
Drug: HTD1801; Placebo · For: Nonalcoholic Steatohepatitis (NASH); Type 2 Diabetes
Sites: Chandler, Arizona; Peoria, Arizona; Tucson, Arizona · 45 sites in all
J2H BiotechIndustry
NCT06297434 · 87 participants · Start Feb 15, 2023 · Primary completion Jun 26, 2025
Drug: J2H-1702; J2H-1702 and 2 more · For: Non-alcoholic Steatohepatitis
Sites: Busan, South Korea; Gyeonggi-do, South Korea; Gyeongsang, South Korea · 11 sites in all
TakedaTakeda (TAK)
NCT02616302 · 71 participants · Start Feb 20, 2023 · Primary completion Jul 21, 2026
Drug: Dexlansoprazole · For: Gastroesophageal Reflux Disease (GERD)
Sites: Mobile, Alabama; San Francisco, California; Atlanta, Georgia · 18 sites in all
- Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERDPivotal-lookingCompleted
Microbiome Health SciencesIndustry
NCT05556824 · 255 participants · Start Mar 3, 2023 · Primary completion May 27, 2026
Drug: MHS-1031 · For: Gastroesophageal Reflux
Sites: Phoenix, Arizona; Los Angeles, California; Lake City, Florida · 18 sites in all
- A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)Pivotal-lookingCompleted
Akero Therapeutics, IncIndustry
NCT05039450 · 213 participants · Start Jul 30, 2021 · Primary completion Dec 15, 2023
Drug: EFX; Placebo · For: NASH - Nonalcoholic Steatohepatitis
Sites: Chandler, Arizona; Glendale, Arizona; Tucson, Arizona · 49 sites in all
Intercept PharmaceuticalsIndustry
NCT05239468 · 72 participants · Start Mar 21, 2022 · Primary completion Sep 1, 2025
Drug: Bezafibrate 100 mg; Bezafibrate 200 mg and 3 more · For: Primary Biliary Cholangitis
Sites: Birmingham, Alabama; Coronado, California; Mission Hills, California · 26 sites in all
- A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis.Pivotal-lookingCompleted
CinDome Pharma, Inc.Industry
NCT06899217 · 416 participants · Start Jan 29, 2025 · Primary completion May 7, 2026
Drug: CIN-102 Dose 15mg; Placebo and 1 more · For: Idiopathic Gastroparesis
Sites: Birmingham, Alabama; Foley, Alabama; Saraland, Alabama · 85 sites in all
- A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an ExtensionPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04880031 · 231 participants · Start Sep 30, 2021 · Primary completion Oct 27, 2025
Drug: Efimosfermin; Placebo · For: Nonalcoholic Steatohepatitis (NASH)
Sites: Birmingham, Alabama; Chandler, Arizona; Peoria, Arizona · 48 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.